NCT00559936

Topical Avastin for Treatment of Corneal Neovascularization

Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Massachusetts Eye and Ear Infirmary · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the effectiveness and safety of Topical Bevacizumab (Avastin) for treatment of corneal neovascularization.

Detailed description

Primary outcomes measures included neovascular area (NA), defined as the area of the corneal vessels themselves; vessel caliber (VC), defined as the mean diameter of the corneal vessels; and invasion area (IA), defined as the fraction of the total cornea into which the vessels extend. The occurrence of ocular and systemic adverse events was closely monitored throughout the course of the study.

Conditions

• Corneal Neovascularization

Interventions

Type	Name	Description
DRUG	Topical Avastin 1%	Avastin (bevacizumab) 1%

Timeline

• Start date: 2007-02-01
• Primary completion: 2010-10-01
• Completion: 2010-10-01
• First posted: 2007-11-16
• Last updated: 2022-04-29
• Results posted: 2012-09-24

Locations

1 site across 1 country: United States